rituximab

Pharma

AZ makes case for Calquence in another blood cancer type

AstraZeneca reported that adding Calquence to standard of care reduced the risk of disease progression or death by 27% in MCL patients.

Kevin Dunleavy Jun 17, 2024 11:25am

NovartisHQClose

Novartis plans more Sandoz ‘autonomy,’ but no spinoff: report

Nov 15, 2018 11:23am